在早期和晚期发病的阿尔茨海默病中,对周血管空间的扩散度的评估
Xiao Luo1, Hui Hong1, Shuyue Wang1
1Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Journal of Alzheimer's disease : JAD
|July 21, 2025
概括
脑脊液 (CSF) 功能障碍,通过DTI-ALPS测量,在早期发病和晚期发病的阿尔茨海默氏症 (AD) 中减少. 这种功能障碍与认知衰退相关,粉样蛋白影响EOAD,年龄/白质变化影响LOAD.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 老年学是一门学科.
背景情况:
- 大脑脊髓液 (CSF) 动态对于清除β-粉样蛋白至关重要,β-粉样蛋白是阿尔茨海默病 (AD) 发病的关键因素.
- 了解早期发病的AD (EOAD) 和晚期发病的AD (LOAD) 之间的CSF功能障碍的差异对于有针对性的治疗策略至关重要.
研究的目的:
- 为了研究和区分EOAD和LOAD亚型之间的脑脊液 (CSF) 功能障碍.
- 为了检查CSF功能障碍与AD患者的大脑变化和认知功能的关联.
主要方法:
- 在40名EOAD患者,38名LOAD患者和年龄匹配的对照组进行了体内成像,包括沿周血管空间的扩散张力成像 (DTI-ALPS).
- 测量了粉样蛋白和蛋白PET SUVR,海马体积和白质超强度 (WMH).
- 统计分析包括ANOVA,Tukey的HSD测试,皮尔森相关性和线性回归来评估群体差异和关系.
主要成果:
- 与对照组相比,EOAD和LOAD患者的DTI-ALPS指数显着较低,表明CSF动态受损.
- 在AD亚型中,较低的DTI-ALPS指数与增加的疾病严重程度和较差的认知表现相关.
- 在EOAD中,减少的DTI-ALPS主要与粉样蛋白负担有关,而在LOAD中,它与年龄和白质过强度 (WMH) 有关.
结论:
- 脑脊液 (CSF) 功能障碍,如DTI-ALPS所示,是EOAD和LOAD的共同特征.
- 不同的潜在机制可能会导致EOAD (粉样蛋白相关) 和LOAD (与年龄和WMH相关) 中的CSF功能障碍.
- 需要进一步的研究来阐明在阿尔茨海默氏病中中脑脊髓功能障碍的这些亚型特异性病因.
更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.3K
07:47Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases
Published on: December 6, 2016
7.2K
相关概念视频
Assessment of Diffusion and Perfusion
1.1K
Understanding and evaluating diffusion and perfusion is critical in assessing a patient's respiratory and circulatory health. These processes play key roles in maintaining the body's internal environment, ensuring that tissues receive adequate oxygen while waste products are efficiently removed.
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
1.1K
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
